Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Published: January 2013
No. of Pages: 60
  

GBI Research, the leading business intelligence provider, has released its latest research, “Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share”, which provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.

Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in the forecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol (fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that the generic sector in the global statins market will grow significantly in the future and will pose tough competition to new molecules.

Scope

  • Data and analysis on the statins market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population.
  • Share of generics in the global statins market.
  • Key drivers and restraints that have had a significant impact on the global statins market.
  • The competitive landscape of the global statins market, including top companies benchmarking. The key companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis.
  • Key M&A activities and licensing agreements that took place in the statins market.

Reasons to buy

  • Align their product portfolio to the markets with high growth potential
  • Build effective strategies to launch their pipeline products by identifying potential geographies
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
  • Develop key strategic initiatives by studying the key strategies of top competitors
  • Devise more tailored country-specific strategies through the understanding of key drivers and barriers and the market potential of each indication for different territories
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious

Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Statins Market to 2018 - Introduction 8

3 Statins Market to 2018 - Global Statins Market 9
3.1 Introduction 9
3.2 Global Market Forecast 10
3.2.1 Branded and Generic Market Share 12
3.3 Annual Cost of Treatment 13
3.4 Treatment Usage Patterns 14
3.4.1 Disease Population 15
3.4.2 Treatment Seeking Population 15
3.4.3 Diagnosed Population 15
3.4.4 Prescription Population 15
3.5 Drivers and Restraints to the Statins Market 16
3.5.1 Drivers to the Statins Market 16
3.5.2 Restraints to the Statins Market 17
3.6 Major Marketed Products 19
3.6.1 Crestor (rosuvastatin calcium) 19
3.6.2 Lipitor (atorvastatin calcium) 20
3.6.3 Vytorin (ezetimibe/simvastatin) 21
3.6.4 Zocor (simvastatin) 22
3.6.5 Livalo (pitavastatin calcium) 22
3.6.6 Lescol XL (fluvastatin sodium) 23
3.6.7 Pravachol (pravastatin sodium) 24

4 Statins Market to 2018 - Statins Market in the US 25
4.1 Market 25
4.2 Annual Cost of Therapy (ACT) 27
4.3 Treatment Usage Pattern 28
4.3.1 Diseased Population 29
4.3.2 Treatment Seeking Population 29
4.3.3 Diagnosed Population 29
4.3.4 Patients on Statins Therapy 29

5 Statins Market to 2018 - Statins Market in the Top Five Countries of Europe 30
5.1 Market 30
5.2 Annual Cost of Therapy 33
5.3 Treatment Usage Pattern 34
5.3.1 Diseased Population 35
5.3.2 Treatment Seeking Population 35
5.3.3 Diagnosed Population 35
5.3.4 Patients on Statins Therapy 35

6 Statins Market to 2018 - Statins Market in Japan 36
6.1 Market 36
6.2 Annual Cost of Therapy 38
6.3 Treatment Usage Pattern 40
6.3.1 Diseased Population 41
6.3.2 Treatment Seeking Population 41
6.3.3 Diagnosed Population 41
6.3.4 Patients on Statins Therapy 41

7 Statins Market to 2018 - Product Pipeline Anlaysis 42
7.1 Introduction 42
7.2 Pipeline Analysis 42

8 Statins Market to 2018 - Competitive Landscape 43
8.1 Pfizer Inc. 44
8.1.1 Company Overview 44
8.1.2 SWOT Analysis 44
8.2 AstraZeneca PLC (AstraZeneca) 45
8.2.1 Company Overview 45
8.2.2 SWOT Analysis 45
8.3 Merck & Co Inc 46
8.3.1 Company Overview 46
8.3.2 SWOT Analysis 46
8.4 Novartis AG (Novartis) 47
8.4.1 Company Overview 47
8.4.2 SWOT Analysis 47

9 Statins Market to 2018 - Strategic Consolidation 48
9.1 Merger and Acquisition (M&A) Deals 48
9.2 Licensing Deals 49
9.2.1 Licensing Deals by Geography 49
9.3 Co-development Deals 51

10 Statins Market to 2018 - Appendix 52
10.1 Market Definitions 52
10.2 Abbreviations 52
10.3 Bibliography 55
10.4 Research Methodology 56
10.4.1 Coverage 56
10.4.2 Secondary Research 56
10.4.3 Primary Research 57
10.4.4 Therapeutic Landscape 57
10.4.5 Geographical Landscape 60
10.4.6 Pipeline Analysis 60
10.4.7 Competitive Landscape 60
10.5 Expert Panel Validation 60
10.6 Contact Us 60
10.7 Disclaimer 60

List of Tables

Table 1: Statins Market, Global, Revenue ($bn), 2004-2011 10
Table 2: Statins Market, Global, Revenue Forecast ($bn), 2011 -2018 10
Table 3: Statins Market, Global, ACT ($), 2004-2011 13
Table 4: Statins Market, Global, ACT ($), 2011-2018 13
Table 5: Statins Market, Global, Treatment Usage Patterns (million), 2004-2011 14
Table 6: Statins Market, Global, Treatment Usage Patterns (million), 2011-2018 14
Table 7: Statins Market, the US, Revenue ($bn), 2004-2011 25
Table 8: Statins Market, the US, Revenue Forecast ($bn), 2011-2018 25
Table 9: Statins Market, the US, ACT ($), 2004-2011 27
Table 10: Statins Market, the US, ACT ($), 2011-2018 27
Table 11: Statins Market, the US, Treatment Usage Pattern (million), 2004-2011 28
Table 12: Statins Market, the US, Treatment Usage Pattern (million), 2011-2018 28
Table 13: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 31
Table 14: Statins Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 31
Table 15: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2011 33
Table 16: Statins Market, Top Five Countries of Europe, ACT ($), 2011-2018 33
Table 17: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004-2011 34
Table 18: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011-2018 34
Table 19: Statins Market, Japan, Revenue ($bn), 2004-2011 36
Table 20: Statins Market, Japan, Revenue Forecast ($bn), 2011-2018 36
Table 21: Statins Market, Japan, ACT ($), 2004-2011 38
Table 22: Statins Market, Japan, ACT ($), 2011-2018 38
Table 23: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2011 40
Table 24: Statins Market, Japan, Treatment Usage Pattern (million), 2011-2018 40
Table 25: Statins Market, Global, Product Pipeline, 2012 42
Table 26: Statins Market, M&A Deals ($m), 2008-2011 48
Table 27: Statins Market, Licensing Deals, 2005-2011 49
Table 28: Statins Market, Co-Development Deals, 2005-2008 51

List of Figures

Figure 1: Statins Market, Global, Revenue ($bn), 2004-2018 10
Figure 2: Statins Market, Global, Generic and Branded Market Share (%), 2011 and 2018 12
Figure 3: Statins Market, Global, ACT ($), 2004-2018 13
Figure 4: Statins Market, Global, Treatment Usage Patterns (million), 2004-2018 14
Figure 5: Statins Market, Global, Drivers and Barriers, 2011 16
Figure 6: Statins Market, the US, Revenue ($bn), 2004 -2018 25
Figure 7: Statins Market, the US, ACT ($), 2004-2018 27
Figure 8: Statins Market, the US, Treatment Usage Pattern (million), 2004-2018 28
Figure 9: Statins Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018 31
Figure 10: Statins Market, Top Five Countries of Europe, ACT ($), 2004-2018 33
Figure 11: Statins Market, Top Five Countries of Europe, Treatment Usage Pattern (million),  2004-2018 34
Figure 12: Statins Market, Japan, Revenue ($bn), 2004-2018 36
Figure 13: Statins Market, Japan, ACT ($), 2004-2018 38
Figure 14: Statins Market, Japan, Treatment Usage Pattern (million), 2004-2018 40
Figure 15: Statins Market, Global, Top Companies’ Market Share (%), 2011 43
Figure 16: Statins Market, Pfizer Inc., SWOT Analysis, 2011 44
Figure 17: Statins Market, AstraZeneca, SWOT Analysis, 2011 45
Figure 18: Statins Market, Merck & Co. Inc., SWOT Analysis, 2011 46
Figure 19: Statins Market, Novartis, SWOT Analysis, 2011 47
Figure 20: Statins Market, Strategic Consolidation, 2005-2011 48
Figure 21: GBI Research Market Forecasting Model 59

Published By: GBI Research
Product Code: GBI Research1385


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100